Merck Submits New Drug Application to the Japanese Pharmaceuticals and Medical Devices Agency for Omarigliptin, an Investigational Once-Weekly DPP-4 Inhibitor for Type 2 Diabetes
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the company has submitted a new drug application
for omarigliptin, its investigational once-weekly DPP-4 inhibitor for
the treatment of type 2 diabetes, to the Japanese Pharmaceuticals and
Medical Devices Agency (PMDA).
Language:
English
Contact:
...
Source: Merck.com - Product News - November 24, 2014 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
VYTORIN® (ezetimibe/simvastatin) Significantly Reduced Cardiovascular Events More than Simvastatin Alone in Patients Presenting with Acute Coronary Syndromes in the Investigational IMPROVE-IT Study
Dateline City:
CHICAGO
CHICAGO--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the investigational IMPROVE-IT study met its
primary and all secondary composite efficacy endpoints.
Language:
English
Contact:
MerckMedia Contact:Pam Eisele, 267-305-3558orInvestor Contact:Joe Romanelli, 908-423-5185
Ticker Slug:
...
Source: Merck.com - Product News - November 17, 2014 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Merck Announces Data from Pivotal Phase 3 Fracture Outcomes Study for Odanacatib, an Investigational Oral, Once-Weekly Treatment for Osteoporosis
Dateline City:
WHITEHOUSE STATION, N.J.
Merck now expects to submit the New Drug Application for odanacatib with the U.S. Food and Drug Administration (FDA) in 2015
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced data from the pivotal Phase 3 fracture outcomes study
for odanacatib in postmenopausal women with osteoporosis. Odanacatib is
Merck’s investigational once-weekly cathepsin K inhibi...
Source: Merck.com - Product News - September 15, 2014 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Merck Receives Accelerated Approval of KEYTRUDA® (pembrolizumab), the First FDA-Approved Anti-PD-1 Therapy
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration (FDA) has
approved KEYTRUDA® (pembrolizumab) at a dose of 2 mg/kg every three
weeks for the treatment of patients with unresectable or metastatic
melanoma and disease progression following ipilimumab and, if BRAF V600
mutation positive, a BRAF inhibitor. This indication is approved under
accelerated approval based on ...
Source: Merck.com - Product News - September 4, 2014 Category: Drugs & Pharmacology Tags: Prescription Medicine News Source Type: news
Merck Statement regarding Role of PNEUMOVAX® 23 (Pneumococcal Vaccine Polyvalent) in Updated ACIP Recommendations for Pneumococcal Vaccination in Adults
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside of the United States and Canada,
today provided the following statement regarding the U.S. Centers for
Disease Control and Prevention’s (CDC’s) Advisory Committee on
Immunization Practices’ (ACIP’s) updated pneumococcal vaccine
recommendations for adults 65 years of age and older.
Language:
English
Contact:
...
Source: Merck.com - Product News - August 13, 2014 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
FDA Approves BELSOMRA® (suvorexant) for the Treatment of Insomnia
Dateline City:
WHITEHOUSE STATION, N.J.
BELSOMRA expected to be available in late 2014 or early 2015
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA) has
approved BELSOMRA® (suvorexant) for adults with insomnia who
have difficulty falling asleep and/or staying asleep. BELSOMRA
(pronounced bell-SOM-rah) is a highly selective antagonist for orexi...
Source: Merck.com - Product News - August 13, 2014 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
FDA Approves Merck’s NOXAFIL® (posaconazole) Injection (18 mg/mL) for Intravenous Use
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
today announced that the U.S. Food and Drug Administration has approved
NOXAFIL® (posaconazole) injection (18 mg/ mL), a new
formulation of NOXAFIL for intravenous (IV) use. Merck’s antifungal
agent is also marketed as NOXAFIL (100 mg) delayed-release tablets and
NOXAFIL (40 mg/mL) oral suspension.
Language:
English
...
Source: Merck.com - Product News - March 14, 2014 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
New 96-Week ACTG Study Results Presented at CROI 2014; First Large Study Comparing ISENTRESS® (raltegravir) Regimen to Two Protease Inhibitor Regimens in Previously Untreated Adults with HIV-1
Dateline City:
BOSTON
BOSTON--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
said today that in a new 96-week, open-label AIDS Clinical Trials Group
(ACTG) study designed to compare three different NNRTI-sparing HIV
regimens in treatment-naïve patients – one containing Merck’s
twice-daily ISENTRESS® (raltegravir) and two containing
different once-daily ritonavir-boosted protease inhibitors, atazanavir
and darunavir -- all three regimens achieved high and equivalent levels
of ...
Source: Merck.com - Product News - March 5, 2014 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Merck Announces Canadian Approval of GRASTEK® (Standardized Allergenic Extract, Timothy Grass (Phleum pratense) Sublingual Tablet)
Dateline City:
WHITEHOUSE STATION, N.J.
GRASTEK (Timothy Grass Pollen Allergen Extract) Remains Under FDA Review in the United States
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today announced the regulatory approval and launch of GRASTEK®
(Timothy grass pollen allergen extract) sublingual tablets in Canada.
This represents the first approval of GRASTEK for Merck. The product is
currently markete...
Source: Merck.com - Product News - February 3, 2014 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
Merck Statement on FDA Advisory Committee for GRASTEK® (Timothy Grass Pollen Allergen Extract), Merck’s Investigational Sublingual Allergy Immunotherapy Tablet
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
today issued the following statement after the conclusion of the
Allergenic Products Advisory Committee of the U.S. Food and Drug
Administration (FDA) meeting to discuss GRASTEK® (Timothy
grass pollen allergen extract).
Language:
English
Contact:
MerckMedia:Pa...
Source: Merck.com - Product News - December 13, 2013 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
ZOSTAVAX® (Zoster Vaccine Live) Awarded Prix Galien USA 2013 Best Biotechnology Product
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada,
announced today that ZOSTAVAX® (Zoster Vaccine Live), the company's
vaccine to help prevent shingles, received the Prix Galien USA 2013
Award for Best Biotechnology Product.
Language:
English
Contact:
Media:MerckCaroline Lappetito, (267) 305-7639 ...
Source: Merck.com - Product News - October 23, 2013 Category: Drugs & Pharmacology Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Merck Presents New Pharmacokinetic Data on ISENTRESS® (raltegravir) at 14th European AIDS Conference
Dateline City:
WHITEHOUSE STATION, N.J.
Company Confirms Development Program for Investigational Once Daily (QD) Dosing Regimen of ISENTRESS
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE:MRK), known as MSD outside the United States and Canada, is
presenting pharmacokinetic data this week on investigational
formulations of a once daily (QD) dose of ISENTRESS at the 14th
European AIDS Conference (EACS), sponsored by the European AIDS Clinical
Society. The me...
Source: Merck.com - Product News - October 16, 2013 Category: Drugs & Pharmacology Tags: Prescription Medicine News Research and Development News Corporate News Latest News Source Type: news
Merck Reaffirms Commitment to State AIDS Drug Assistance Programs (ADAPs) Through 2014
Dateline City:
WHITEHOUSE STATION, N.J.
Merck (NYSE: MRK), known as MSD outside the United States and Canada, and the ADAP Crisis Task Force (ACTF) today announced that the company will extend its commitment to support state AIDS Drug Assistance Programs (ADAPs), which have struggled to meet growing needs in recent years due to funding shortfalls. Through the new agreement, which extends through Dec.
Language:
English
read more (Source: Merck.com - Product News)
Source: Merck.com - Product News - July 29, 2013 Category: Drugs & Pharmacology Authors: Maria.tortoreto at merck.com Tags: ACTF Isentress Merck MRK MSD NASTAD Prescription Medicine News Corporate News Corporate Responsibility News Latest News Source Type: news
FDA Approves New U.S. Labeling for ISENTRESS® (raltegravir) to Include 240-Week Results from STARTMRK Study of ISENTRESS Containing Regimen in Previously Untreated HIV-1 Infected Adult Patients
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside the United States and Canada,
announced today that the U.S. Food and Drug Administration (FDA) has
approved new labeling for ISENTRESS® (raltegravir)
Film-coated Tablets, Merck’s integrase inhibitor for the treatment of
HIV-1 infection in adult patients as part of combination HIV therapy.
Language:
English
Contact:
...
Source: Merck.com - Product News - July 1, 2013 Category: Drugs & Pharmacology Authors: hq_site_admin Tags: Prescription Medicine News Corporate News Latest News Source Type: news
Merck Welcomes Independent Review of the Safety Profile of JANUVIA® (sitagliptin) and Other Diabetes Medicines
Dateline City:
WHITEHOUSE STATION, N.J.
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Merck, known as MSD outside the United States and Canada, today issued
the following statement regarding this week's NIDDK-NCI Workshop and the
American Diabetes Association’s (ADA) call for an independent review of
data about the safety of incretin-based diabetes medicines, including
GLP-1 analogs and DPP-4 inhibitors such as JANUVIA®
(sitagliptin).
Language:
English
...
Source: Merck.com - Product News - June 12, 2013 Category: Drugs & Pharmacology Authors: hq_site_admin Tags: Prescription Medicine News Corporate News Latest News Source Type: news
